Millipore acquires NovAseptic AB

Millipore Corporation announced that it has completed the acquisition of over 90% of the shares of NovAseptic AB: the acquisition broadens their offering to the Biotech and Pharmaceutical industries

Millipore Corporation announced that it has completed the acquisition of over 90% of the shares of NovAseptic AB from the company's majority shareholders.

Millipore is in the process of acquiring the remaining shares from the minority shareholders.

Martin Madaus, Millipore Chairman, CEO and President, noted: "NovAseptic brings innovative and differentiated products that our biotech and pharmaceutical customers value highly for manufacturing biologics and for monitoring bio-manufacturing processes.

There is a great fit strategically and tactically, and we've added exceptional technology and talent to Millipore".

NovAseptic, based in Gothenburg, Sweden, provides a range of innovative solutions for aseptic processing applications in biotech and pharmaceutical manufacturing operations.

The patented NovaSeptum disposable sampling system is used by biotech and pharmaceutical companies to take fluid samples from their drug manufacturing processes, eliminating the risk of false positives due to biological contaminants.

NovaSeptum has been adopted by a number of pharmaceutical and biotechnology companies, and several new evaluations are in progress.

The other NovAseptic aseptic processing components include high-performance mixers and valves, optimally designed for performance and reliability in stringent drug production environments.

These components enjoy an exceptional quality reputation with customers.

Back to top